Pharvaris (PHVS) Share-based Compensation (2020 - 2026)
Pharvaris (PHVS) posted Share-based Compensation of $5.7 million for Q1 2026, up 8.56% on a QoQ basis from $5.3 million in Q4 2025, and up 32.07% year-over-year from $4.3 million in Q1 2025.
Pharvaris (PHVS) Share-based Compensation (2020 - 2026) Analysis & Trends
Pharvaris' Share-based Compensation history runs 7 years deep, the most recent figure standing at $5.7 million for Q1 2026.
- Quarterly Share-based Compensation rose 32.07% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.0 million (up 19.05% YoY) and the FY2025 annual result came in at $21.5 million, up 22.69% from the prior year.
- Share-based Compensation was $5.7 million for Q1 2026 at Pharvaris, up from $5.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $5771.1 billion in Q2 2023 and bottomed at -$5769.3 billion in Q3 2023.
- A 5-year average of $108.1 million and a median of $4.2 million in 2024 frame the typical range for Share-based Compensation.
- Peak annual rise in Share-based Compensation reached 172087079.47% in 2023, while the deepest fall reached 187987220.43% in 2023.
- Pharvaris' Share-based Compensation stood at $3.3 million in 2022, then fell by 18.73% to $2.7 million in 2023, then soared by 93.92% to $5.2 million in 2024, then climbed by 2.16% to $5.3 million in 2025, then grew by 8.56% to $5.7 million in 2026.
- Business Quant data shows PHVS's Share-based Compensation at $5.7 million in Q1 2026, $5.3 million in Q4 2025, and $5.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Pharvaris | 2.17 Bn | 1.88 Bn | - | 5.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.73 Mn |
| Mar 31, 2026 | 5.73 Mn |
| Dec 31, 2025 | 5.28 Mn |
| Dec 31, 2025 | 5.28 Mn |
| Sep 30, 2025 | 5.71 Mn |
| Sep 30, 2025 | 5.71 Mn |
| Jun 30, 2025 | 6.22 Mn |
| Jun 30, 2025 | 6.22 Mn |
| Mar 31, 2025 | 4.34 Mn |
| Mar 31, 2025 | 4.34 Mn |
| Dec 31, 2024 | 5.17 Mn |
| Dec 31, 2024 | 5.17 Mn |
| Sep 30, 2024 | 5.58 Mn |
| Sep 30, 2024 | 5.58 Mn |
| Jun 30, 2024 | 4.19 Mn |
| Jun 30, 2024 | 4.19 Mn |
| Mar 31, 2024 | 2.61 Mn |
| Mar 31, 2024 | 2.61 Mn |
| Dec 31, 2023 | 2.67 Mn |
| Dec 31, 2023 | 2.67 Mn |